Steven Rowe, MD
Urology · Middletown, NYNPI 1164416897
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Ambu Inc. at 43.3% of the total. That places this record below the midpoint for urology clinicians in NY, where the typical reported total is $2,467.
Across 3 payments — averaging $79.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ambu Inc.$103
- Bioprotect Medical, Inc.$92
- Procept Biorobotics Corporation$43
Across 43 payments — averaging $4646.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$182K
- Sumitomo Pharma America, Inc.$12K
- Urovant Sciences Inc$6K
What the payments were for
- Food & beverage$239100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ambu Inc. | 1 | $103 |
| Bioprotect Medical, Inc. | 1 | $92 |
| Procept Biorobotics Corporation | 1 | $43 |
How this compares
$239 in reported general payments places this provider in the 15th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 202 | $119,888 |
| GemtesaVibegron | 58 | $33,568 |
| Tamsulosin Hcl | 1,370 | $19,216 |
| Potassium Citrate ErPotassium Citrate | 119 | $8,739 |
| Oxybutynin Chloride ErOxybutynin Chloride | 327 | $8,505 |
| Estradiol | 67 | $6,623 |
| Finasteride | 562 | $6,071 |
| Testosterone | 23 | $4,606 |
| Tadalafil | 39 | $3,136 |
| Tolterodine Tartrate ErTolterodine Tartrate | 32 | $2,993 |
| Trospium Chloride | 31 | $2,546 |
| Doxazosin Mesylate | 147 | $2,252 |
| Methenamine Hippurate | 22 | $2,123 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 125 | $1,838 |
| Silodosin | 20 | $1,377 |
Paid to pharmacies, not to this prescriber.
Other urology in Middletown
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Evan GoldfischerPoughkeepsie$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.